Core Insights - Conavi Medical has appointed Mark Quick as Chief Financial Officer to support its U.S. expansion and commercialization efforts for the Novasight Hybrid imaging system [1][3][5] - The company has submitted its next-generation Novasight Hybrid IVUS/OCT system to the FDA for 510(k) clearance, aiming for a successful launch in the U.S. market [2][5] - Stefano Picone transitions to a strategic role as Chief Strategy Officer, focusing on ensuring continuity during the company's growth phase [1][4][5] Leadership Changes - Mark Quick brings over 20 years of experience in medical technology and life sciences, having held senior financial roles in publicly traded companies [3][6] - Stefano Picone has played a crucial role in Conavi's previous growth phases and will now concentrate on strategic execution [4][5] Product Development - The Novasight Hybrid System is the first device to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT), allowing simultaneous imaging of coronary arteries [7] - The first-generation Novasight Hybrid System has already received regulatory clearance in multiple countries, including the U.S., Canada, China, and Japan [7] Market Strategy - The company is actively building the necessary infrastructure to support its U.S. launch, which is critical as the U.S. is the largest market for intravascular imaging [2][5] - Leadership changes are aligned with the company's strategy to enhance its presence in the capital markets and ensure successful commercialization [1][5]